Review
Sep 2026
Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.
Tocilizumab has been proposed as a third-line therapy for refractory autoimmune encephalitis; pediatric Latin American data remain limited. OBJECTIVE To evaluate the efficacy and safety of tocilizumab in pediatric patients with severe or refractory anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. MATERIALS...
R. Garcia, Andrea Del Rocío Quiroz Saavedra, María Celeste Buompadre et al.
· Brain & development (Tokyo.... · 0 citations